Mohamed Hamid

Dr. Mohamed Hamid

Minia University, Faculty of Medicine
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2021 in Cells
Verified
Journal Article
Open access
PDF file
Mohamed HamidMohamed Hamid
Mohamed Hamid
MMM. Tarek Moustafa
M. Tarek Moustafa
SNSonali Nashine
Sonali Nashine
RCRodrigo Donato Costa
Rodrigo Donato Costa
KSKevin Schneider
Kevin Schneider
Maria Cristina KenneyMaria Cristina Kenney
Maria Cristina Kenney
Our study assesses the effects of anti-VEGF (Vascular Endothelial Growth Factor) drugs and Trichostatin A (TSA), an inhibitor of histone deacetylase (HDAC) activity, on cultured ARPE-19 (Adult Retinal Pigment Epithelial-19) cells that are immortalized human retinal pigment epithelial cells. ARPE-19 cells were treated with the following anti-VEGF drugs: aflibercept, ranibizumab, or bevacizumab at 1× and 2× concentrations of the clinical intravitreal dose (12.5 μL/mL and 25 μL/mL, respectively) and analyzed for transcription profiles of genes associated with the pathogenesis age-related macular degeneration (AMD). HDAC activity was measured using the Fluorometric Histone Deacetylase assay. TSA downregulated HIF-1α and IL-1β genes, and upregulated BCL2L13, CASPASE-9, and IL-18 genes. TSA alone or bevacizumab plus TSA showed a significant reduction of HDAC activity compared to untreated ARPE-19 cells. Bevacizumab alone did not significantly alter HDAC activity, but increased gene expression of SOD2, BCL2L13, CASPASE-3, and IL-18 and caused downregulation of HIF-1α and IL-18. Combination of bevacizumab plus TSA increased gene expression of SOD2, HIF-1α, GPX3A, BCL2L13, and CASPASE-3, and reduced CASPASE-9 and IL-β. In conclusion, we demonstrated that anti-VEGF drugs can: (1) alter expression of genes involved in oxidative stress (GPX3A and SOD2), inflammation (IL-18 and IL-1β) and apoptosis (BCL2L13, CASPASE-3, and CASPASE-9), and (2) TSA-induced deacetylation altered transcription for angiogenesis (HIF-1α), apoptosis, and inflammation genes.

1 June 2020 in Clinical Ophthalmology
Verified
Journal Article
Open access
PDF file
HAHeba Radi AttaAllah
Heba Radi AttaAllah
AMAsmaa Anwar Mohamed Mohamed
Asmaa Anwar Mohamed Mohamed
Mohamed HamidMohamed Hamid
Mohamed Hamid
Purpose: To investigate macular structural and microvascular changes in retinitis pigmentosa (RP) eyes compared to age-matched controls using spectral domain optical coherence tomography (SD-OCT) and OCT angiography (OCTA). Methods: This was a cross-sectional study. The foveal and parafoveal thickness and extent of ellipsoid zone (EZ) disruption were measured on OCT. The foveal avascular zone (FAZ) area and retinal vessel density (VD) were automatically calculated for superficial (SCP) and deep capillary plexuses (DCP) and choriocapillaris using OCTA-integrated software. VD was assessed for the whole 6 × 6 mm image, foveal and parafoveal regions. Quantitative measures were compared between healthy and diseased eyes. Results: The study included 30 eyes of 30 RP patients and 24 eyes of 24 controls. Mean age was 26.9± 6.4 years for RP patients and 27.4± 4.9 years for controls (p=0.76). Mean LogMAR visual acuity (VA) was 0.9± 0.5 for RP patients and 0.05± 0.05 for controls (p < 0.001). Foveal and parafoveal thicknesses were significantly lower in RP cases as compared to the control group. EZ disruption was observed in RP cases only (869± 211 μm). Mean FAZ area was significantly larger in RP eyes in both SCP and DCP. VD was significantly reduced in RP eyes at the level of SCP, DCP and choriocapillaris. VA, deep parafoveal VD, foveal, parafoveal and whole image choriocapillaris VD were negatively correlated with the extent of EZ disruption. Conclusion: We report OCTA findings in a relatively young cohort of RP patients. We demonstrated a reduction of retinal microvascular density in all studied layers on OCTA. We believe studying retinal vasculature in these patients is important, as a healthy blood supply is a prerequisite for the success of new cell-based therapies under trial for RP.

1 April 2021 in International Journal of Retina and Vitreous
Verified
Journal Article
Open access
PDF file
Mohamed HamidMohamed Hamid
Mohamed Hamid
NANizar S. Abdelfattah
Nizar S. Abdelfattah
JSJamshid Salamzadeh
Jamshid Salamzadeh
SASahar T. A. Abdelaziz
Sahar T. A. Abdelaziz
ASAhmed M. Sabry
Ahmed M. Sabry
BKBaruch D. Kuppermann
Baruch D. Kuppermann
Background: Despite the good outcomes achieved with intravitreal angiogenic therapy, a subset of neovascular age-related macular degeneration (AMD) patients experience resistance to therapy after repeated injections. Switching drugs could offer benefit to this group of patients. Purpose: To determine visual and anatomical outcomes in a cohort of neovascular AMD patients resistant to repeated injections of bevacizumab/ranibizumab after switching to aflibercept therapy. Methods: This was a retrospective chart review of patients who had a diagnosis of neovascular AMD and persistent intraretinal (IRF) and/or subretinal fluid (SRF) on optical coherence tomography (OCT) for at least 3 months despite monthly bevacizumab and/or ranibizumab injections prior to transition to aflibercept. We reviewed patients’ records and OCT images obtained at baseline, 1, 3, 6 and 12 months after transition to aflibercept. Data collected included demographics, best-corrected visual acuity (BCVA), number of injections received and the occurrence of any adverse events. Studied OCT parameters included central macular thickness (CMT) values and the presence or absence of SRF, IRF and/or pigment epithelial detachment (PED) at each visit. Results: We included 53 eyes of 48 patients. Mean change in BCVA from baseline was 0.05 ± 0.13 (P = 0.01) at M1, 0.04 ± 0.16 (P = 0.08) at M3, 0.01 ± 0.22 (P = 0.9) at M6, and 0.02 ± 0.28 (P = 1) at M12, while the mean change in CMT from baseline was 64 ± 75 μm (P < 0.0001) at M1, 42 ± 85 μm (P = 0.002) at M3, 47 ± 69 μm (P < 0.0001) at M6, and 46 ± 99 μm (P = 0.001) at M12. The percentage of eyes with SRF decreased from 77.4% at baseline to 39.6% at M1, then increased to 47.2% at M3, then decreased to 43.4% at M6, and to 41.5% at M12 (All p < 0.001, compared to baseline). Compared to baseline, there was a statistically significant decrease in the percentage of eyes having IRF from 47.2 to 20.8% at M1 (p < 0.001), 30.2% at M3, 24.5% at M6 and 26.4% at M12 (p < 0.01, each). The number of bevacizumab and/or ranibizumab injections (7.36 ± 1.85) was significantly higher than that of aflibercept (6.47 ± 2.45, p = 0.001). A significant direct relationship between CMT reduction and BCVA improvement was demonstrated at M1 (p = 0.01, r = 0.36), M3 (p = 0.03, r = 0.30) and M12 (p = 0.03, r = 0.30). Eyes with IRF had significantly poorer BCVA than eyes without IRF at baseline (p = 0.02) and M3 (p = 0.04). Conclusion: Switching to intravitreal aflibercept therapy in a cohort of neovascular AMD patients resistant to chronic bevacizumab and/or ranibizumab injections can lead to significant visual improvement in the short term and sustained reduction of central macular thickness over 1 year of followup.

1 January 2020 in Clinical Ophthalmology
Verified
Journal Article
Open access
PDF file
HMHossam Eldeen Mohammad Moharram
Hossam Eldeen Mohammad Moharram
AAAhmed Shawkat Mohamed Abdelhalim
Ahmed Shawkat Mohamed Abdelhalim
Mohamed HamidMohamed Hamid
Mohamed Hamid
MAMohamed Farouk Abdelkader
Mohamed Farouk Abdelkader
Purpose: The purpose of this study is to compare anatomical and visual outcomes after using silicone oil (SO) or C 3F 8 gas as tamponades after pars plana vitrectomy (PPV) for retinal detachment (RD) associated with giant retinal tears (GRTs). Methods: A retrospective chart review was conducted for cases that underwent PPV for GRT-associated RD. We excluded eyes that had prior vitreoretinal surgery, a history of ocular trauma or worse than grade B proliferative vitreoretinopathy (PVR). Baseline demographic and ocular characteristics, surgical details and postoperative anatomical and visual outcomes were recorded and statistically analyzed. Results: We included 88 eyes; 48 eyes had C 3F 8 gas and 40 eyes had SO as a tamponading agent. Mean age was 39 years. All eyes underwent 23G PPV with no adjuvant scleral buckling and phacovitrectomy was performed for all phakic eyes. Final retinal reattachment was achieved in 86 eyes (97.7%). One eye from each group had recurrent RD. Postoperative vision was significantly better in the gas group (p= 0.008). Prolonged increase of IOP developed in 6 eyes in the SO group and 5 eyes in the gas group. Prolonged uveitis developed in 4 eyes in the gas group and 6 eyes in the oil group (P= 0.04). Epiretinal membranes (ERM) developed in 10 eyes in the gas group and 9 eyes in the oil group. We found no significant difference between both groups regarding postoperative glaucoma or ERM formation. Conclusion: Both agents achieved similar favorable anatomical outcomes in a series of eyes with fresh GRT-associated RD and low-grade PVR, with better visual outcome and less frequent uveitis associated with the use of gas tamponade.

1 February 2020 in Experimental Eye Research
Verified
Journal Article
Open access
JCJavier Cáceres-Del-Carpio
Javier Cáceres-Del-Carpio
MMM. Tarek Moustafa
M. Tarek Moustafa
JTJaime Toledo-Corral
Jaime Toledo-Corral
Mohamed HamidMohamed Hamid
Mohamed Hamid
SAShari R. Atilano
Shari R. Atilano
BKBaruch D. Kuppermann
Baruch D. Kuppermann

1 August 2021 in Clinical Ophthalmology
Verified
Journal Article
Open access
PDF file
MMMohamed Salah El-Din Mahmoud
Mohamed Salah El-Din Mahmoud
Mohamed HamidMohamed Hamid
Mohamed Hamid
MAMohamed Farouk Abdelkader
Mohamed Farouk Abdelkader
Purpose: To study tear film and corneal thickness measurements in systemic lupus erythematosus (SLE) patients compared to age-matched controls using anterior segment optical coherence tomography (AS-OCT). Methods: This was a cross-sectional study. Study participants were divided into 3 groups: Group A: SLE patients with clinical dry eye, Group B: SLE patients without clinical dry eye and Group C: healthy controls. The lower tear meniscus parameters measured using AS-OCT were tear meniscus height (TMH), tear meniscus depth (TMD) and tear meniscus area (TMA). The central corneal and corneal epithelial thickness were automatically calculated. Results: The study included 40 eyes in Group A, 60 in Group B, and 100 in Group C. Mean age was 26.9± 6.6 years for Group A, 27.6± 7.3 years for Group B and 35.7± 9.2 years for Group C (p= 0.06). All subjects were females except for 1 male patient in Group A. Mean TMH, TMA and TMD in Group C were 487.7± 185.6 μm, 0.068± 0.040 mm2, and 341.2± 99.1 μm, respectively, which was significantly higher compared to Group A (225.5± 27.9 μm, 0.018± 0.004 mm2 and 171.9± 26.0 μm, respectively, all p < 0.001) and Group B (395.4± 118.8 μm, p < 0.001; 0.05± 0.04 mm2, p=0.016 and 280.6± 93.4 μm, p < 0.001, respectively). Group B eyes also had significantly higher parameters compared to Group A (all p < 0.001). Mean corneal and epithelial thickness in Group C were 501.6± 37.5 μm and 53.3± 4.5 μm, respectively, which was significantly higher compared to Group A (496.1± 24.1 μm, p=0.044 and 49.5± 3.5 μm, p < 0.001, respectively) and Group B (504.2± 22.03 μm, p=0.046 and 47.5± 5.6 μm, p < 0.001, respectively). Group B eyes also had a significantly higher corneal thickness (p=0.031) and epithelial thickness (p=0.011) compared to Group A. Conclusion: We demonstrated significant reduction of tear meniscus dimensions, central corneal thickness and epithelial thickness in SLE patients compared to age-matched controls using AS-OCT.